+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

21 June 2019
Pharma

Visiongain has launched a new pharma report Global (IBD) Drug Market Report: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis, Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.

IBD incidence and prevalence is evolving worldwide and is now anticipated to be an emerging global disease. The inflammatory bowel diseases (IBD) drug market will continue to be driven by rising disease incidence and more-effective non-invasive diagnosis.

The lead analyst of the report commented "Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis. Economic development of newly industrialized countries is expected to intensify, and several developing countries will make the transition to the status of newly industrialized countries. The magnitude of the growth of IBD in newly industrialized countries will depend on several factors, including exposure to relevant environmental risk factors, urbanization of the population, access to health care, the speed of adoption of medical technologies such as colonoscopy, and natural population growth. Advances in electronic surveillance of diseases will also enhance reporting of IBD from many regions that currently lack data."

Leading companies featured in the report include AbbVie, Allergan, Biogen, Celgene Corporation, Gilead Sciences, Janssen, Novartis, Pfizer, Roche, Takeda, UCB Pharma S.A. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

Read

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

Read

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

Read

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever